JP2012509877A5

JP2012509877A5 -

Download PDF

Info

Publication number: JP2012509877A5
Authority: JP; Japan
Prior art keywords: alkyl; group; amino; dihydro; pyrrolo
Prior art date: 2009-11-16
Legal status : Granted

Application number

JP2011537535A

Other languages

English (en)

Japanese (ja)

Other versions

JP5501369B2 (ja

JP2012509877A (ja

Filing date

2009-11-16

Publication date

2013-05-02

2009-11-16 Application filed filed Critical

2009-11-16 Priority claimed from PCT/US2009/064570 external-priority patent/WO2010065275A1/en

2012-04-26 Publication of JP2012509877A publication Critical patent/JP2012509877A/ja

2013-05-02 Publication of JP2012509877A5 publication Critical patent/JP2012509877A5/ja

2014-05-21 Application granted granted Critical

2014-05-21 Publication of JP5501369B2 publication Critical patent/JP5501369B2/ja

Status Expired - Fee Related legal-status Critical Current

2029-11-16 Anticipated expiration legal-status Critical

Links

150000001875 compounds Chemical class 0.000 claims description 142
125000003118 aryl group Chemical group 0.000 claims description 49
239000000203 mixture Substances 0.000 claims description 43
-1 2,3,6-trifluorobenzyl Chemical group 0.000 claims description 38
150000003839 salts Chemical class 0.000 claims description 36
125000001072 heteroaryl group Chemical group 0.000 claims description 33
102000007637 Soluble Guanylyl Cyclase Human genes 0.000 claims description 28
108010007205 Soluble Guanylyl Cyclase Proteins 0.000 claims description 28
125000000217 alkyl group Chemical group 0.000 claims description 28
238000011282 treatment Methods 0.000 claims description 22
125000000753 cycloalkyl group Chemical group 0.000 claims description 20
125000001424 substituent group Chemical group 0.000 claims description 19
239000003814 drug Substances 0.000 claims description 18
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
230000002265 prevention Effects 0.000 claims description 14
229910052739 hydrogen Inorganic materials 0.000 claims description 13
239000008194 pharmaceutical composition Substances 0.000 claims description 13
125000000304 alkynyl group Chemical group 0.000 claims description 12
206010019280 Heart failures Diseases 0.000 claims description 11
238000002360 preparation method Methods 0.000 claims description 11
125000003342 alkenyl group Chemical group 0.000 claims description 10
206010020772 Hypertension Diseases 0.000 claims description 9
208000035475 disorder Diseases 0.000 claims description 9
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
208000002815 pulmonary hypertension Diseases 0.000 claims description 7
125000000714 pyrimidinyl group Chemical group 0.000 claims description 7
201000001320 Atherosclerosis Diseases 0.000 claims description 6
208000010125 myocardial infarction Diseases 0.000 claims description 6
208000024172 Cardiovascular disease Diseases 0.000 claims description 5
208000010228 Erectile Dysfunction Diseases 0.000 claims description 5
208000006011 Stroke Diseases 0.000 claims description 5
208000007536 Thrombosis Diseases 0.000 claims description 5
229910052799 carbon Inorganic materials 0.000 claims description 5
230000001684 chronic effect Effects 0.000 claims description 5
206010012601 diabetes mellitus Diseases 0.000 claims description 5
201000001881 impotence Diseases 0.000 claims description 5
206010002383 Angina Pectoris Diseases 0.000 claims description 4
206010052337 Diastolic dysfunction Diseases 0.000 claims description 4
206010016654 Fibrosis Diseases 0.000 claims description 4
208000006673 asthma Diseases 0.000 claims description 4
230000007882 cirrhosis Effects 0.000 claims description 4
208000019425 cirrhosis of liver Diseases 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
230000003511 endothelial effect Effects 0.000 claims description 4
208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 4
230000008085 renal dysfunction Effects 0.000 claims description 4
208000037803 restenosis Diseases 0.000 claims description 4
125000000464 thioxo group Chemical group S=* 0.000 claims description 4
RMQPTENEQUQKPM-UHFFFAOYSA-N 4-amino-2-[5-chloro-3-(3,3,3-trifluoropropyl)indazol-1-yl]-5,5-dimethyl-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N1=C(CCC(F)(F)F)C2=CC(Cl)=CC=C2N1C1=NC(N)=C2C(C)(C)C(=O)NC2=N1 RMQPTENEQUQKPM-UHFFFAOYSA-N 0.000 claims description 3
GTDUMDPQHXDMIF-UHFFFAOYSA-N 4-amino-2-[5-chloro-3-[(2,3,6-trifluorophenyl)methyl]indazol-1-yl]-5,5-dimethyl-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N=1C(N)=C2C(C)(C)C(=O)NC2=NC=1N(C1=CC=C(Cl)C=C11)N=C1CC1=C(F)C=CC(F)=C1F GTDUMDPQHXDMIF-UHFFFAOYSA-N 0.000 claims description 3
BNSOCYVUMZHUCC-UHFFFAOYSA-N 4-amino-2-[6-chloro-3-[(2,3,6-trifluorophenyl)methyl]imidazo[1,5-a]pyridin-1-yl]-5,5-dimethyl-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N=1C(N)=C2C(C)(C)C(=O)NC2=NC=1C(=C1C=CC(Cl)=CN11)N=C1CC1=C(F)C=CC(F)=C1F BNSOCYVUMZHUCC-UHFFFAOYSA-N 0.000 claims description 3
RINOAIDLQRSFNM-UHFFFAOYSA-N 4-amino-2-[6-fluoro-3-[(2,3,6-trifluorophenyl)methyl]imidazo[1,5-a]pyridin-1-yl]-5,5-dimethyl-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N=1C(N)=C2C(C)(C)C(=O)NC2=NC=1C(=C1C=CC(F)=CN11)N=C1CC1=C(F)C=CC(F)=C1F RINOAIDLQRSFNM-UHFFFAOYSA-N 0.000 claims description 3
VMZULFAWLYUBHF-UHFFFAOYSA-N 4-amino-5,5-dimethyl-2-[3-[(2,3,6-trifluorophenyl)methyl]thieno[3,4-c]pyrazol-1-yl]-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N=1C(N)=C2C(C)(C)C(=O)NC2=NC=1N(C1=CSC=C11)N=C1CC1=C(F)C=CC(F)=C1F VMZULFAWLYUBHF-UHFFFAOYSA-N 0.000 claims description 3
ZLJFGARUWCRSOM-UHFFFAOYSA-N 4-amino-5,5-dimethyl-2-[7-[(2,3,6-trifluorophenyl)methyl]imidazo[1,5-b]pyridazin-5-yl]-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N=1C(N)=C2C(C)(C)C(=O)NC2=NC=1C(=C1C=CC=NN11)N=C1CC1=C(F)C=CC(F)=C1F ZLJFGARUWCRSOM-UHFFFAOYSA-N 0.000 claims description 3
125000004043 oxo group Chemical group O=* 0.000 claims description 3
239000002461 renin inhibitor Substances 0.000 claims description 3
229940086526 renin-inhibitors Drugs 0.000 claims description 3
LDVSSXAHTIRBCH-UHFFFAOYSA-N 4-amino-2-[3-(2-cyclopentylethyl)imidazo[1,5-a]pyridin-1-yl]-5,5-dimethyl-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N=1C(N)=C2C(C)(C)C(=O)NC2=NC=1C(=C1C=CC=CN11)N=C1CCC1CCCC1 LDVSSXAHTIRBCH-UHFFFAOYSA-N 0.000 claims description 2
XBHFTYMFIFAJGD-UHFFFAOYSA-N 4-amino-2-[3-[(2,3-difluorophenyl)methyl]-6-fluoroimidazo[1,5-a]pyridin-1-yl]-5,5-dimethyl-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N=1C(N)=C2C(C)(C)C(=O)NC2=NC=1C(=C1C=CC(F)=CN11)N=C1CC1=CC=CC(F)=C1F XBHFTYMFIFAJGD-UHFFFAOYSA-N 0.000 claims description 2
OIEHSMGMADBLND-UHFFFAOYSA-N 4-amino-5,5-dimethyl-2-[3-[(2,3,6-trifluorophenyl)methyl]imidazo[1,5-a]pyridin-1-yl]-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N=1C(N)=C2C(C)(C)C(=O)NC2=NC=1C(=C1C=CC=CN11)N=C1CC1=C(F)C=CC(F)=C1F OIEHSMGMADBLND-UHFFFAOYSA-N 0.000 claims description 2
239000005541 ACE inhibitor Substances 0.000 claims description 2
101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims description 2
101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims description 2
229940127291 Calcium channel antagonist Drugs 0.000 claims description 2
239000000695 adrenergic alpha-agonist Substances 0.000 claims description 2
239000002170 aldosterone antagonist Substances 0.000 claims description 2
229940083712 aldosterone antagonist Drugs 0.000 claims description 2
239000002333 angiotensin II receptor antagonist Substances 0.000 claims description 2
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 2
150000001540 azides Chemical class 0.000 claims description 2
125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 2
239000002876 beta blocker Substances 0.000 claims description 2
239000000480 calcium channel blocker Substances 0.000 claims description 2
239000002934 diuretic Substances 0.000 claims description 2
239000002792 enkephalinase inhibitor Substances 0.000 claims description 2
230000002503 metabolic effect Effects 0.000 claims description 2
239000000810 peripheral vasodilating agent Substances 0.000 claims description 2
229960002116 peripheral vasodilator Drugs 0.000 claims description 2
239000004036 potassium channel stimulating agent Substances 0.000 claims description 2
125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 claims description 2
230000002889 sympathetic effect Effects 0.000 claims description 2
229940124549 vasodilator Drugs 0.000 claims description 2
239000003071 vasodilator agent Substances 0.000 claims description 2
125000001475 halogen functional group Chemical group 0.000 claims 9
208000024891 symptom Diseases 0.000 claims 5
239000013543 active substance Substances 0.000 claims 2
MTKHTHGSENYUKD-UHFFFAOYSA-N 4-amino-2-[5-chloro-3-(3,3,4,4,4-pentafluorobutyl)indazol-1-yl]-5,5-dimethyl-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N1=C(CCC(F)(F)C(F)(F)F)C2=CC(Cl)=CC=C2N1C1=NC(N)=C2C(C)(C)C(=O)NC2=N1 MTKHTHGSENYUKD-UHFFFAOYSA-N 0.000 claims 1
IPIVNHNRKIZAIM-UHFFFAOYSA-N 4-amino-2-[5-fluoro-3-(3,3,4,4,4-pentafluorobutyl)indazol-1-yl]-5,5-dimethyl-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N1=C(CCC(F)(F)C(F)(F)F)C2=CC(F)=CC=C2N1C1=NC(N)=C2C(C)(C)C(=O)NC2=N1 IPIVNHNRKIZAIM-UHFFFAOYSA-N 0.000 claims 1
IQMOLHCNOMCYGD-UHFFFAOYSA-N 4-amino-2-[6-chloro-1-(3,3,4,4,4-pentafluorobutyl)indazol-3-yl]-5,5-dimethyl-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound ClC1=CC=C2C(C=3N=C4NC(=O)C(C4=C(N)N=3)(C)C)=NN(CCC(F)(F)C(F)(F)F)C2=C1 IQMOLHCNOMCYGD-UHFFFAOYSA-N 0.000 claims 1
NUNLZPOOGCWTAC-UHFFFAOYSA-N 4-amino-2-[6-chloro-3-(3,3,4,4,4-pentafluorobutyl)imidazo[1,5-a]pyridin-1-yl]-5,5-dimethyl-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N1=C(CCC(F)(F)C(F)(F)F)N2C=C(Cl)C=CC2=C1C1=NC(N)=C2C(C)(C)C(=O)NC2=N1 NUNLZPOOGCWTAC-UHFFFAOYSA-N 0.000 claims 1
LGEFDAIYRJCBED-UHFFFAOYSA-N 4-amino-2-[6-fluoro-3-(3,3,4,4,4-pentafluorobutyl)imidazo[1,5-a]pyridin-1-yl]-5,5-dimethyl-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N1=C(CCC(F)(F)C(F)(F)F)N2C=C(F)C=CC2=C1C1=NC(N)=C2C(C)(C)C(=O)NC2=N1 LGEFDAIYRJCBED-UHFFFAOYSA-N 0.000 claims 1
QQSMPMVFCSGBAG-UHFFFAOYSA-N 4-amino-5,5-dimethyl-2-[3-(3,3,4,4,4-pentafluorobutyl)imidazo[1,5-a]pyridin-1-yl]-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N1=C(CCC(F)(F)C(F)(F)F)N2C=CC=CC2=C1C1=NC(N)=C2C(C)(C)C(=O)NC2=N1 QQSMPMVFCSGBAG-UHFFFAOYSA-N 0.000 claims 1
UTLSMDLPOWJEDJ-UHFFFAOYSA-N 4-amino-5,5-dimethyl-2-[3-(3,3,4,4,4-pentafluorobutyl)indazol-1-yl]-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N1=C(CCC(F)(F)C(F)(F)F)C2=CC=CC=C2N1C1=NC(N)=C2C(C)(C)C(=O)NC2=N1 UTLSMDLPOWJEDJ-UHFFFAOYSA-N 0.000 claims 1
102000010180 Endothelin receptor Human genes 0.000 claims 1
108050001739 Endothelin receptor Proteins 0.000 claims 1
208000031226 Hyperlipidaemia Diseases 0.000 claims 1
230000003213 activating effect Effects 0.000 claims 1
239000000674 adrenergic antagonist Substances 0.000 claims 1
229940126317 angiotensin II receptor antagonist Drugs 0.000 claims 1
239000005557 antagonist Substances 0.000 claims 1
230000001882 diuretic effect Effects 0.000 claims 1
229940126585 therapeutic drug Drugs 0.000 claims 1
239000000243 solution Substances 0.000 description 94
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 88
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 63
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 57
239000000543 intermediate Substances 0.000 description 49
238000006243 chemical reaction Methods 0.000 description 44
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 42
238000005481 NMR spectroscopy Methods 0.000 description 39
235000019439 ethyl acetate Nutrition 0.000 description 37
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 34
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 31
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 31
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 30
239000012267 brine Substances 0.000 description 28
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 28
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
239000002904 solvent Substances 0.000 description 27
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
239000007787 solid Substances 0.000 description 26
238000000034 method Methods 0.000 description 23
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 21
239000012074 organic phase Substances 0.000 description 21
ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 20
239000000047 product Substances 0.000 description 20
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 17
239000011541 reaction mixture Substances 0.000 description 17
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 16
125000005843 halogen group Chemical group 0.000 description 16
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
239000012044 organic layer Substances 0.000 description 14
238000003756 stirring Methods 0.000 description 14
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
238000004949 mass spectrometry Methods 0.000 description 13
IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 11
230000002829 reductive effect Effects 0.000 description 11
238000010898 silica gel chromatography Methods 0.000 description 11
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 10
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 10
210000004027 cell Anatomy 0.000 description 10
238000010828 elution Methods 0.000 description 10
0 *CC(CCCC(*)CC1)CCCC1c1nc(N)c(C(*)(*)C(N2)=O)c2n1 Chemical compound *CC(CCCC(*)CC1)CCCC1c1nc(N)c(C(*)(*)C(N2)=O)c2n1 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 9
230000000694 effects Effects 0.000 description 9
239000000706 filtrate Substances 0.000 description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
229940079593 drug Drugs 0.000 description 8
239000003480 eluent Substances 0.000 description 8
239000001257 hydrogen Substances 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000007924 injection Substances 0.000 description 8
150000002576 ketones Chemical class 0.000 description 8
239000000741 silica gel Substances 0.000 description 8
229910002027 silica gel Inorganic materials 0.000 description 8
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 7
125000004429 atom Chemical group 0.000 description 7
239000002585 base Substances 0.000 description 7
239000003054 catalyst Substances 0.000 description 7
201000010099 disease Diseases 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
238000004007 reversed phase HPLC Methods 0.000 description 7
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
230000004913 activation Effects 0.000 description 6
PBLJCNOEDTVFLD-UHFFFAOYSA-N amino(chloromethyl)aluminum Chemical compound N[Al]CCl PBLJCNOEDTVFLD-UHFFFAOYSA-N 0.000 description 6
238000003556 assay Methods 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
125000001153 fluoro group Chemical group F* 0.000 description 6
150000002500 ions Chemical class 0.000 description 6
150000002825 nitriles Chemical class 0.000 description 6
229910052757 nitrogen Inorganic materials 0.000 description 6
239000003921 oil Substances 0.000 description 6
235000019198 oils Nutrition 0.000 description 6
239000000825 pharmaceutical preparation Substances 0.000 description 6
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
239000000126 substance Substances 0.000 description 6
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 5
QRAZASHLGLHKEB-UHFFFAOYSA-N 2-(2,3,6-trifluorophenyl)acetic acid Chemical compound OC(=O)CC1=C(F)C=CC(F)=C1F QRAZASHLGLHKEB-UHFFFAOYSA-N 0.000 description 5
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
125000004432 carbon atom Chemical group C* 0.000 description 5
238000003818 flash chromatography Methods 0.000 description 5
125000005842 heteroatom Chemical group 0.000 description 5
125000000623 heterocyclic group Chemical group 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 5
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 5
125000002950 monocyclic group Chemical group 0.000 description 5
230000000638 stimulation Effects 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
239000003643 water by type Substances 0.000 description 5
238000005160 1H NMR spectroscopy Methods 0.000 description 4
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
229910021595 Copper(I) iodide Inorganic materials 0.000 description 4
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
108010078321 Guanylate Cyclase Proteins 0.000 description 4
102000014469 Guanylate cyclase Human genes 0.000 description 4
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
150000001409 amidines Chemical class 0.000 description 4
239000000969 carrier Substances 0.000 description 4
238000000132 electrospray ionisation Methods 0.000 description 4
235000019253 formic acid Nutrition 0.000 description 4
150000003278 haem Chemical class 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
230000014759 maintenance of location Effects 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
238000000746 purification Methods 0.000 description 4
238000010992 reflux Methods 0.000 description 4
WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 4
229910000104 sodium hydride Inorganic materials 0.000 description 4
239000012312 sodium hydride Substances 0.000 description 4
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
229910052938 sodium sulfate Inorganic materials 0.000 description 4
235000011152 sodium sulphate Nutrition 0.000 description 4
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
238000004809 thin layer chromatography Methods 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 3
KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
UBDZFAGVPPMTIT-UHFFFAOYSA-N 2-aminoguanidine;hydron;chloride Chemical compound [Cl-].NC(N)=N[NH3+] UBDZFAGVPPMTIT-UHFFFAOYSA-N 0.000 description 3
BAZVFQBTJPBRTJ-UHFFFAOYSA-N 2-chloro-5-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(Cl)N=C1 BAZVFQBTJPBRTJ-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
229910004298 SiO 2 Inorganic materials 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
239000012190 activator Substances 0.000 description 3
239000000654 additive Substances 0.000 description 3
150000001408 amides Chemical class 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
125000001309 chloro group Chemical group Cl* 0.000 description 3
WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
229940125936 compound 42 Drugs 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical class CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
239000003446 ligand Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
229910052763 palladium Inorganic materials 0.000 description 3
239000003208 petroleum Substances 0.000 description 3
238000012746 preparative thin layer chromatography Methods 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
238000007363 ring formation reaction Methods 0.000 description 3
238000000926 separation method Methods 0.000 description 3
239000002002 slurry Substances 0.000 description 3
229910052717 sulfur Inorganic materials 0.000 description 3
239000000725 suspension Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
239000011701 zinc Substances 0.000 description 3
229910052725 zinc Inorganic materials 0.000 description 3
JRHPOFJADXHYBR-HTQZYQBOSA-N (1r,2r)-1-n,2-n-dimethylcyclohexane-1,2-diamine Chemical compound CN[C@@H]1CCCC[C@H]1NC JRHPOFJADXHYBR-HTQZYQBOSA-N 0.000 description 2
ULIYQAUQKZDZOX-UHFFFAOYSA-N 1,1,1-trifluoro-3-iodopropane Chemical compound FC(F)(F)CCI ULIYQAUQKZDZOX-UHFFFAOYSA-N 0.000 description 2
BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
206010002388 Angina unstable Diseases 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
229910015900 BF3 Inorganic materials 0.000 description 2
KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical group O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
208000007718 Stable Angina Diseases 0.000 description 2
208000007814 Unstable Angina Diseases 0.000 description 2
230000009471 action Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
239000000908 ammonium hydroxide Substances 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
125000002619 bicyclic group Chemical group 0.000 description 2
WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
239000000292 calcium oxide Substances 0.000 description 2
ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 2
150000001717 carbocyclic compounds Chemical class 0.000 description 2
239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
229940117975 chromium trioxide Drugs 0.000 description 2
GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 description 2
238000004891 communication Methods 0.000 description 2
229940127573 compound 38 Drugs 0.000 description 2
229910052802 copper Inorganic materials 0.000 description 2
239000010949 copper Substances 0.000 description 2
ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
239000012043 crude product Substances 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
229910052805 deuterium Inorganic materials 0.000 description 2
ISOLMABRZPQKOV-UHFFFAOYSA-N diethyl 2-acetamidopropanedioate Chemical compound CCOC(=O)C(NC(C)=O)C(=O)OCC ISOLMABRZPQKOV-UHFFFAOYSA-N 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
230000006806 disease prevention Effects 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000008298 dragée Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
HCRBXQFHJMCTLF-ZCFIWIBFSA-N ethyl (2r)-2-methylbutanoate Chemical compound CCOC(=O)[C@H](C)CC HCRBXQFHJMCTLF-ZCFIWIBFSA-N 0.000 description 2
PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
239000000833 heterodimer Substances 0.000 description 2
150000007857 hydrazones Chemical class 0.000 description 2
150000002431 hydrogen Chemical class 0.000 description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
238000005984 hydrogenation reaction Methods 0.000 description 2
FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 2
239000007943 implant Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
201000004332 intermediate coronary syndrome Diseases 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
239000004310 lactic acid Substances 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
238000000691 measurement method Methods 0.000 description 2
BIECSXCXIXHDBC-UHFFFAOYSA-N methyl 2-bromo-5-chlorobenzoate Chemical compound COC(=O)C1=CC(Cl)=CC=C1Br BIECSXCXIXHDBC-UHFFFAOYSA-N 0.000 description 2
ZXUQEPZWVQIOJE-UHFFFAOYSA-N methyl 2-chloro-2-oxoacetate Chemical compound COC(=O)C(Cl)=O ZXUQEPZWVQIOJE-UHFFFAOYSA-N 0.000 description 2
239000003094 microcapsule Substances 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 2
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
239000007922 nasal spray Substances 0.000 description 2
239000012454 non-polar solvent Substances 0.000 description 2
PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 2
230000037361 pathway Effects 0.000 description 2
239000008177 pharmaceutical agent Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
239000006187 pill Substances 0.000 description 2
WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
230000010118 platelet activation Effects 0.000 description 2
229920005862 polyol Polymers 0.000 description 2
150000003077 polyols Chemical class 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
150000003217 pyrazoles Chemical class 0.000 description 2
PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
125000004076 pyridyl group Chemical group 0.000 description 2
238000010791 quenching Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
230000004043 responsiveness Effects 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
239000011734 sodium Substances 0.000 description 2
235000010288 sodium nitrite Nutrition 0.000 description 2
239000007858 starting material Substances 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000000829 suppository Substances 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 2
VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
BZMMRNKDONDVIB-UHFFFAOYSA-N (1-ethoxycyclopropyl)oxy-trimethylsilane Chemical compound CCOC1(O[Si](C)(C)C)CC1 BZMMRNKDONDVIB-UHFFFAOYSA-N 0.000 description 1
GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
UXOWGYHJODZGMF-IYQSZBERSA-N (2s)-5-amino-n-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-2-propan-2-ylnonanamide Chemical compound COCCCOC1=CC(CC(CC(N)C(O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-IYQSZBERSA-N 0.000 description 1
BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
IYZRFOAPEUBNQP-JPZLKUPGSA-N (3s)-n-[(2s)-1-[[(5s)-5-amino-6-hydroxyhexyl]amino]-4-methyl-1-oxopentan-2-yl]-3-hydroxy-4-[[3-(1h-imidazol-5-yl)-2-[[3-naphthalen-1-yl-2-(naphthalen-1-ylmethyl)propanoyl]amino]propanoyl]amino]-6-methylheptanamide;dihydrochloride Chemical compound Cl.Cl.C=1C=CC2=CC=CC=C2C=1CC(CC=1C2=CC=CC=C2C=CC=1)C(=O)NC(C(=O)NC(CC(C)C)[C@@H](O)CC(=O)N[C@@H](CC(C)C)C(=O)NCCCC[C@H](N)CO)CC1=CN=CN1 IYZRFOAPEUBNQP-JPZLKUPGSA-N 0.000 description 1
SYPWPWUSXPWLKW-ZQWQDMLBSA-N (3s,4s)-5-cyclohexyl-n-hexyl-3-hydroxy-4-[[(2s)-2-[[(2s)-2-[(2-morpholin-4-ylacetyl)amino]-3-naphthalen-1-ylpropanoyl]amino]-3-(1,3-thiazol-4-yl)propanoyl]amino]pentanamide Chemical compound C([C@@H]([C@@H](O)CC(=O)NCCCCCC)NC(=O)[C@H](CC=1N=CSC=1)NC(=O)[C@H](CC=1C2=CC=CC=C2C=CC=1)NC(=O)CN1CCOCC1)C1CCCCC1 SYPWPWUSXPWLKW-ZQWQDMLBSA-N 0.000 description 1
KQJKUOYVWLBSDN-UHFFFAOYSA-N (5-chloropyridin-2-yl)methanamine Chemical compound NCC1=CC=C(Cl)C=N1 KQJKUOYVWLBSDN-UHFFFAOYSA-N 0.000 description 1
OALKYGZLLCDVEN-UHFFFAOYSA-N (5-fluoropyridin-2-yl)methanamine Chemical compound NCC1=CC=C(F)C=N1 OALKYGZLLCDVEN-UHFFFAOYSA-N 0.000 description 1
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
LNDGACQEAYKNOI-UHFFFAOYSA-N 1,1,1-trifluoro-4-iodobutane Chemical compound FC(F)(F)CCCI LNDGACQEAYKNOI-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
IVVNZDGDKPTYHK-JTQLQIEISA-N 1-cyano-2-[(2s)-3,3-dimethylbutan-2-yl]-3-pyridin-4-ylguanidine Chemical compound CC(C)(C)[C@H](C)N=C(NC#N)NC1=CC=NC=C1 IVVNZDGDKPTYHK-JTQLQIEISA-N 0.000 description 1
125000006017 1-propenyl group Chemical group 0.000 description 1
LZMHWZHOZLVYDL-UHFFFAOYSA-N 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one Chemical compound C1=CC=C2N3C(=O)ON=C3C=NC2=C1 LZMHWZHOZLVYDL-UHFFFAOYSA-N 0.000 description 1
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
REHRQXVEAXFIML-UHFFFAOYSA-N 1h-indazole-3-carbonitrile Chemical compound C1=CC=C2C(C#N)=NNC2=C1 REHRQXVEAXFIML-UHFFFAOYSA-N 0.000 description 1
VEKHJWHWWJCKRM-UHFFFAOYSA-N 1h-pyridazine-2-carbonitrile Chemical compound N#CN1NC=CC=C1 VEKHJWHWWJCKRM-UHFFFAOYSA-N 0.000 description 1
GHXNRYVDXNZXID-UHFFFAOYSA-N 2,2-diethylbutanoic acid Chemical compound CCC(CC)(CC)C(O)=O GHXNRYVDXNZXID-UHFFFAOYSA-N 0.000 description 1
OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
NNJBQTDFDVLWEQ-UHFFFAOYSA-N 2-(sulfonylamino)benzoic acid Chemical class OC(=O)C1=CC=CC=C1N=S(=O)=O NNJBQTDFDVLWEQ-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
CJUCIKJLMFVWIS-UHFFFAOYSA-N 2-bromo-5-fluorobenzaldehyde Chemical compound FC1=CC=C(Br)C(C=O)=C1 CJUCIKJLMFVWIS-UHFFFAOYSA-N 0.000 description 1
NZCKTGCKFJDGFD-UHFFFAOYSA-N 2-bromobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Br NZCKTGCKFJDGFD-UHFFFAOYSA-N 0.000 description 1
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
125000006029 2-methyl-2-butenyl group Chemical group 0.000 description 1
NVBHWAQBDJEGEO-UHFFFAOYSA-N 2-propan-2-ylidenepropanedinitrile Chemical compound CC(C)=C(C#N)C#N NVBHWAQBDJEGEO-UHFFFAOYSA-N 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
MPOYBFYHRQBZPM-UHFFFAOYSA-N 3h-pyridin-4-one Chemical class O=C1CC=NC=C1 MPOYBFYHRQBZPM-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
WCIPUCQTDRHQQN-UHFFFAOYSA-N 4-amino-2-[3-(2-cyclopentylethyl)indazol-1-yl]-5,5-dimethyl-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N=1C(N)=C2C(C)(C)C(=O)NC2=NC=1N(C1=CC=CC=C11)N=C1CCC1CCCC1 WCIPUCQTDRHQQN-UHFFFAOYSA-N 0.000 description 1
YKQOLYRKSULSEH-UHFFFAOYSA-N 4-amino-2-[5-bromo-3-[(2,3,6-trifluorophenyl)methyl]indazol-1-yl]-5,5-dimethyl-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N=1C(N)=C2C(C)(C)C(=O)NC2=NC=1N(C1=CC=C(Br)C=C11)N=C1CC1=C(F)C=CC(F)=C1F YKQOLYRKSULSEH-UHFFFAOYSA-N 0.000 description 1
WTVIUXVKBSATIC-UHFFFAOYSA-N 4-amino-2-[5-chloro-3-(3,3,3-trifluoropropyl)indazol-1-yl]-5-ethyl-5-methyl-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N1=C(CCC(F)(F)F)C2=CC(Cl)=CC=C2N1C1=NC(N)=C2C(CC)(C)C(=O)NC2=N1 WTVIUXVKBSATIC-UHFFFAOYSA-N 0.000 description 1
UFQOTFRVYYIROR-UHFFFAOYSA-N 4-amino-2-[5-chloro-3-(3,3,3-trifluoropropyl)indazol-1-yl]-5-methyl-5-propyl-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N1=C(CCC(F)(F)F)C2=CC(Cl)=CC=C2N1C1=NC(N)=C2C(CCC)(C)C(=O)NC2=N1 UFQOTFRVYYIROR-UHFFFAOYSA-N 0.000 description 1
KOADFYZDPBYHMS-UHFFFAOYSA-N 4-amino-2-[5-chloro-3-[(2,3,6-trifluorophenyl)methyl]indazol-1-yl]-5,5-dimethyl-6,8-dihydropyrido[2,3-d]pyrimidin-7-one Chemical compound N=1C(N)=C2C(C)(C)CC(=O)NC2=NC=1N(C1=CC=C(Cl)C=C11)N=C1CC1=C(F)C=CC(F)=C1F KOADFYZDPBYHMS-UHFFFAOYSA-N 0.000 description 1
SFWAFLSRPHMCOY-UHFFFAOYSA-N 4-amino-5,5-dimethyl-2-[1-(3,3,3-trifluoropropyl)indazol-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound C1=CC=C2C(C=3N=C4NC(=O)C(C4=C(N)N=3)(C)C)=NN(CCC(F)(F)F)C2=C1 SFWAFLSRPHMCOY-UHFFFAOYSA-N 0.000 description 1
MLQBAGZGQVHARD-UHFFFAOYSA-N 4-amino-5,5-dimethyl-2-[1-[(2,3,6-trifluorophenyl)methyl]imidazo[1,5-a]pyridin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N=1C(N)=C2C(C)(C)C(=O)NC2=NC=1C(N1C=CC=CC1=1)=NC=1CC1=C(F)C=CC(F)=C1F MLQBAGZGQVHARD-UHFFFAOYSA-N 0.000 description 1
VRNJNDYQJZFTEU-UHFFFAOYSA-N 4-amino-5,5-dimethyl-2-[3-(3,3,3-trifluoropropyl)indazol-1-yl]-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N1=C(CCC(F)(F)F)C2=CC=CC=C2N1C1=NC(N)=C2C(C)(C)C(=O)NC2=N1 VRNJNDYQJZFTEU-UHFFFAOYSA-N 0.000 description 1
MDMPNGIEAMTYPN-UHFFFAOYSA-N 4-amino-5,5-dimethyl-2-[3-(4,4,4-trifluorobutyl)thieno[3,4-c]pyrazol-1-yl]-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound NC1=C2C(C)(C)C(=O)NC2=NC(N2C3=CSC=C3C(CCCC(F)(F)F)=N2)=N1 MDMPNGIEAMTYPN-UHFFFAOYSA-N 0.000 description 1
JXGISTLZZAWIMG-UHFFFAOYSA-N 4-amino-5,5-dimethyl-2-[3-[(2,3,6-trifluorophenyl)methyl]-4,6-dihydrothieno[3,4-c]pyrazol-1-yl]-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N=1C(N)=C2C(C)(C)C(=O)NC2=NC=1N(C=1CSCC=11)N=C1CC1=C(F)C=CC(F)=C1F JXGISTLZZAWIMG-UHFFFAOYSA-N 0.000 description 1
NXIBFDKAAHJUKJ-UHFFFAOYSA-N 4-amino-5,5-dimethyl-2-[3-[(2,3,6-trifluorophenyl)methyl]indazol-1-yl]-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N=1C(N)=C2C(C)(C)C(=O)NC2=NC=1N(C1=CC=CC=C11)N=C1CC1=C(F)C=CC(F)=C1F NXIBFDKAAHJUKJ-UHFFFAOYSA-N 0.000 description 1
CZKWQJXJHILCNX-UHFFFAOYSA-N 4-amino-5,5-dimethyl-2-[5-[(2,3,6-trifluorophenyl)methyl]imidazo[5,1-b][1,3]thiazol-7-yl]-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N=1C(N)=C2C(C)(C)C(=O)NC2=NC=1C(=C1SC=CN11)N=C1CC1=C(F)C=CC(F)=C1F CZKWQJXJHILCNX-UHFFFAOYSA-N 0.000 description 1
JHIBXTRFACUYLZ-UHFFFAOYSA-N 4-amino-5,5-dimethyl-2-[5-pyridin-4-yl-3-[(2,3,6-trifluorophenyl)methyl]indazol-1-yl]-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N=1C(N)=C2C(C)(C)C(=O)NC2=NC=1N(C1=CC=C(C=C11)C=2C=CN=CC=2)N=C1CC1=C(F)C=CC(F)=C1F JHIBXTRFACUYLZ-UHFFFAOYSA-N 0.000 description 1
ZDVHJQOCVBTMOF-UHFFFAOYSA-N 4-bromothiophene-3-carbaldehyde Chemical compound BrC1=CSC=C1C=O ZDVHJQOCVBTMOF-UHFFFAOYSA-N 0.000 description 1
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
FHHHOYXPRDYHEZ-COXVUDFISA-N Alacepril Chemical compound CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FHHHOYXPRDYHEZ-COXVUDFISA-N 0.000 description 1
UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 description 1
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
101800001288 Atrial natriuretic factor Proteins 0.000 description 1
102400001282 Atrial natriuretic peptide Human genes 0.000 description 1
101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
208000012639 Balance disease Diseases 0.000 description 1
XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 1
102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 1
101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 1
239000002083 C09CA01 - Losartan Substances 0.000 description 1
239000004072 C09CA03 - Valsartan Substances 0.000 description 1
239000002053 C09CA06 - Candesartan Substances 0.000 description 1
239000005537 C09CA07 - Telmisartan Substances 0.000 description 1
NBLVEQAUYWJZRE-UHFFFAOYSA-N C=[I]C1C=CC(F)=C(Cc2ncc3[n]2nccc3)C1I Chemical compound C=[I]C1C=CC(F)=C(Cc2ncc3[n]2nccc3)C1I NBLVEQAUYWJZRE-UHFFFAOYSA-N 0.000 description 1
KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 1
ZWCCHBLDCZPBGR-UHFFFAOYSA-O CCC=CC(CNC(Cc(c(F)ccc1F)c1F)=O)=N[NH3+] Chemical compound CCC=CC(CNC(Cc(c(F)ccc1F)c1F)=O)=N[NH3+] ZWCCHBLDCZPBGR-UHFFFAOYSA-O 0.000 description 1
VSCLIBRTSJKIEI-UHFFFAOYSA-N CS(=O)(=O)C1=C(C=C(C=C1Cl)Cl)C(=O)O Chemical compound CS(=O)(=O)C1=C(C=C(C=C1Cl)Cl)C(=O)O VSCLIBRTSJKIEI-UHFFFAOYSA-N 0.000 description 1
UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
LLUYLWGSENHGAL-UHFFFAOYSA-N Cc1c(cccc2)[n]2c(C)n1 Chemical compound Cc1c(cccc2)[n]2c(C)n1 LLUYLWGSENHGAL-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
PYQXVIWHEIQSJQ-UHFFFAOYSA-N Cl.NCN1NC=CC=C1 Chemical compound Cl.NCN1NC=CC=C1 PYQXVIWHEIQSJQ-UHFFFAOYSA-N 0.000 description 1
229940126639 Compound 33 Drugs 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
TVZCRIROJQEVOT-CABCVRRESA-N Cromakalim Chemical compound N1([C@@H]2C3=CC(=CC=C3OC([C@H]2O)(C)C)C#N)CCCC1=O TVZCRIROJQEVOT-CABCVRRESA-N 0.000 description 1
VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 1
108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
239000012594 Earle’s Balanced Salt Solution Substances 0.000 description 1
108010061435 Enalapril Proteins 0.000 description 1
206010048554 Endothelial dysfunction Diseases 0.000 description 1
229940118365 Endothelin receptor antagonist Drugs 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
102000008015 Hemeproteins Human genes 0.000 description 1
108010089792 Hemeproteins Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
229940122355 Insulin sensitizer Drugs 0.000 description 1
206010048620 Intracardiac thrombus Diseases 0.000 description 1
102000004310 Ion Channels Human genes 0.000 description 1
108090000862 Ion Channels Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000270322 Lepidosauria Species 0.000 description 1
108010007859 Lisinopril Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
ZTULNMNIVVMLIU-UHFFFAOYSA-N Methyl 2-methylpentanoate Chemical compound CCCC(C)C(=O)OC ZTULNMNIVVMLIU-UHFFFAOYSA-N 0.000 description 1
NMMIHXMBOZYNET-UHFFFAOYSA-N Methyl picolinate Chemical compound COC(=O)C1=CC=CC=N1 NMMIHXMBOZYNET-UHFFFAOYSA-N 0.000 description 1
ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
IRLWJILLXJGJTD-UHFFFAOYSA-N Muraglitazar Chemical compound C1=CC(OC)=CC=C1OC(=O)N(CC(O)=O)CC(C=C1)=CC=C1OCCC1=C(C)OC(C=2C=CC=CC=2)=N1 IRLWJILLXJGJTD-UHFFFAOYSA-N 0.000 description 1
RKEFYXWKVMZPLT-LKYARZNKSA-N N=C(/C=C/C=C\C=C\NCCC(F)(F)F)C#N Chemical compound N=C(/C=C/C=C\C=C\NCCC(F)(F)F)C#N RKEFYXWKVMZPLT-LKYARZNKSA-N 0.000 description 1
FEEDIJGZGQJBLJ-UHFFFAOYSA-N N=C(Cc1cc(F)ccc1F)C1=CCCC=N1 Chemical compound N=C(Cc1cc(F)ccc1F)C1=CCCC=N1 FEEDIJGZGQJBLJ-UHFFFAOYSA-N 0.000 description 1
FMMGECJZMRUNAZ-UHFFFAOYSA-N N=C(c1ccccc1C[IH2])C#N Chemical compound N=C(c1ccccc1C[IH2])C#N FMMGECJZMRUNAZ-UHFFFAOYSA-N 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
239000005480 Olmesartan Substances 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
101150003085 Pdcl gene Proteins 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
ZPHBZEQOLSRPAK-UHFFFAOYSA-N Phosphoramidon Natural products C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O ZPHBZEQOLSRPAK-UHFFFAOYSA-N 0.000 description 1
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
NQRYJNQNLNOLGT-UHFFFAOYSA-O Piperidinium(1+) Chemical group C1CC[NH2+]CC1 NQRYJNQNLNOLGT-UHFFFAOYSA-O 0.000 description 1
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
238000000297 Sandmeyer reaction Methods 0.000 description 1
PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
TWZOYAWHWDRMEZ-UHFFFAOYSA-N Thiazolylethylamine Chemical compound NCCC1=NC=CS1 TWZOYAWHWDRMEZ-UHFFFAOYSA-N 0.000 description 1
108010036928 Thiorphan Proteins 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
OQQVFCKUDYMWGV-UHFFFAOYSA-N [5-[1-(phenylmethyl)-3-indazolyl]-2-furanyl]methanol Chemical compound O1C(CO)=CC=C1C(C1=CC=CC=C11)=NN1CC1=CC=CC=C1 OQQVFCKUDYMWGV-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
WEVYAHXRMPXWCK-FIBGUPNXSA-N acetonitrile-d3 Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000001361 adipic acid Substances 0.000 description 1
235000011037 adipic acid Nutrition 0.000 description 1
229950007884 alacepril Drugs 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
229960004601 aliskiren Drugs 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
239000002160 alpha blocker Substances 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
CJCSPKMFHVPWAR-JTQLQIEISA-N alpha-methyl-L-dopa Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
229940093740 amino acid and derivative Drugs 0.000 description 1
HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
229960000528 amlodipine Drugs 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
230000000702 anti-platelet effect Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
150000001502 aryl halides Chemical class 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000012131 assay buffer Substances 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
229960002274 atenolol Drugs 0.000 description 1
229960005370 atorvastatin Drugs 0.000 description 1
YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 description 1
229960004530 benazepril Drugs 0.000 description 1
230000008901 benefit Effects 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
229960003237 betaine Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
229960002781 bisoprolol Drugs 0.000 description 1
VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
239000000872 buffer Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000003222 cGMP degradation Effects 0.000 description 1
FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
229910000024 caesium carbonate Inorganic materials 0.000 description 1
BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
229960000932 candesartan Drugs 0.000 description 1
SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 1
229960000830 captopril Drugs 0.000 description 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
150000004657 carbamic acid derivatives Chemical class 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
229960004195 carvedilol Drugs 0.000 description 1
NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000017455 cell-cell adhesion Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000013626 chemical specie Substances 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229910000423 chromium oxide Inorganic materials 0.000 description 1
HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 1
229960005025 cilazapril Drugs 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000004040 coloring Methods 0.000 description 1
239000013065 commercial product Substances 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
229940125797 compound 12 Drugs 0.000 description 1
229940125851 compound 27 Drugs 0.000 description 1
229940126214 compound 3 Drugs 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229950004210 cromakalim Drugs 0.000 description 1
229960003280 cupric chloride Drugs 0.000 description 1
125000000392 cycloalkenyl group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
229960005227 delapril Drugs 0.000 description 1
WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 description 1
230000005595 deprotonation Effects 0.000 description 1
238000010537 deprotonation reaction Methods 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
GDLBFKVLRPITMI-UHFFFAOYSA-N diazoxide Chemical compound ClC1=CC=C2NC(C)=NS(=O)(=O)C2=C1 GDLBFKVLRPITMI-UHFFFAOYSA-N 0.000 description 1
229960004042 diazoxide Drugs 0.000 description 1
BSHICDXRSZQYBP-UHFFFAOYSA-N dichloromethane;palladium(2+) Chemical compound [Pd+2].ClCCl BSHICDXRSZQYBP-UHFFFAOYSA-N 0.000 description 1
HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
229960004166 diltiazem Drugs 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
LZWLLMFYVGUUAL-UHFFFAOYSA-L ditert-butyl(cyclopenta-1,3-dien-1-yl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.CC(C)(C)P(C(C)(C)C)C1=CC=C[CH-]1.CC(C)(C)P(C(C)(C)C)C1=CC=C[CH-]1 LZWLLMFYVGUUAL-UHFFFAOYSA-L 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
229960001389 doxazosin Drugs 0.000 description 1
230000001280 effect on cGMP Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
229960000873 enalapril Drugs 0.000 description 1
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
229960002680 enalaprilat Drugs 0.000 description 1
LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 description 1
ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
230000008694 endothelial dysfunction Effects 0.000 description 1
239000002308 endothelin receptor antagonist Substances 0.000 description 1
208000002854 epidermolysis bullosa simplex superficialis Diseases 0.000 description 1
SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
239000001813 ethyl (2R)-2-methylbutanoate Substances 0.000 description 1
229940090910 ethyl 2-methylbutyrate Drugs 0.000 description 1
IBQNOZUTEGYQFI-UHFFFAOYSA-N ethyl 4,4-dicyano-3,3-dimethylbutanoate Chemical compound CCOC(=O)CC(C)(C)C(C#N)C#N IBQNOZUTEGYQFI-UHFFFAOYSA-N 0.000 description 1
TXVJSWLZYQMWPC-UHFFFAOYSA-N ethynylcyclopentane Chemical group C#CC1CCCC1 TXVJSWLZYQMWPC-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
229960000815 ezetimibe Drugs 0.000 description 1
239000003925 fat Substances 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
229960002490 fosinopril Drugs 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
101150036617 fu gene Proteins 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
238000002825 functional assay Methods 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
229960001381 glipizide Drugs 0.000 description 1
239000000174 gluconic acid Substances 0.000 description 1
235000012208 gluconic acid Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229940126514 guanylate cyclase activator Drugs 0.000 description 1
239000003119 guanylate cyclase activator Substances 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
150000002391 heterocyclic compounds Chemical class 0.000 description 1
125000006038 hexenyl group Chemical group 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229960002474 hydralazine Drugs 0.000 description 1
229960002003 hydrochlorothiazide Drugs 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
229910000042 hydrogen bromide Inorganic materials 0.000 description 1
USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
125000000687 hydroquinonyl group Chemical class C1(O)=C(C=C(O)C=C1)* 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
229960001195 imidapril Drugs 0.000 description 1
KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 1
IOVNDGHLLJOCHA-UHFFFAOYSA-N imidazol-2-one 1H-pyrrole Chemical class N=1C(N=CC1)=O.N1C=CC=C1 IOVNDGHLLJOCHA-UHFFFAOYSA-N 0.000 description 1
125000002632 imidazolidinyl group Chemical group 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
230000006698 induction Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000003999 initiator Substances 0.000 description 1
229940030980 inova Drugs 0.000 description 1
229960004903 invert sugar Drugs 0.000 description 1
230000026045 iodination Effects 0.000 description 1
238000006192 iodination reaction Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
DXDRHHKMWQZJHT-FPYGCLRLSA-N isoliquiritigenin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O DXDRHHKMWQZJHT-FPYGCLRLSA-N 0.000 description 1
JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 1
235000008718 isoliquiritigenin Nutrition 0.000 description 1
125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
230000000155 isotopic effect Effects 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000010410 layer Substances 0.000 description 1
230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
229960002394 lisinopril Drugs 0.000 description 1
RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
UTEFBSAVJNEPTR-RGEXLXHISA-N loprazolam Chemical compound C1CN(C)CCN1\C=C/1C(=O)N2C3=CC=C([N+]([O-])=O)C=C3C(C=3C(=CC=CC=3)Cl)=NCC2=N\1 UTEFBSAVJNEPTR-RGEXLXHISA-N 0.000 description 1
229960003019 loprazolam Drugs 0.000 description 1
229960004773 losartan Drugs 0.000 description 1
KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
229960004844 lovastatin Drugs 0.000 description 1
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
BLQJIBCZHWBKSL-UHFFFAOYSA-L magnesium iodide Chemical compound [Mg+2].[I-].[I-] BLQJIBCZHWBKSL-UHFFFAOYSA-L 0.000 description 1
229910001641 magnesium iodide Inorganic materials 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
RGPGEMGZZATIQL-UHFFFAOYSA-H magnesium;dipotassium;disodium;trisulfate Chemical compound [Na+].[Na+].[Mg+2].[K+].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RGPGEMGZZATIQL-UHFFFAOYSA-H 0.000 description 1
LZFCBBSYZJPPIV-UHFFFAOYSA-M magnesium;hexane;bromide Chemical compound [Mg+2].[Br-].CCCCC[CH2-] LZFCBBSYZJPPIV-UHFFFAOYSA-M 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
229960003105 metformin Drugs 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
239000001159 methyl (2R)-2-methylpentanoate Substances 0.000 description 1
RBCUIRIGTNHLPS-UHFFFAOYSA-N methyl 2,5-dibromobenzoate Chemical compound COC(=O)C1=CC(Br)=CC=C1Br RBCUIRIGTNHLPS-UHFFFAOYSA-N 0.000 description 1
AXHFSSFWCXKUCS-UHFFFAOYSA-N methyl 2-(dicyanomethyl)-2-methylbutanoate Chemical compound N#CC(C#N)C(C)(CC)C(=O)OC AXHFSSFWCXKUCS-UHFFFAOYSA-N 0.000 description 1
VHMRQLVENVHHJN-UHFFFAOYSA-N methyl 2-(dicyanomethyl)-2-methylpentanoate Chemical compound CCCC(C)(C(C#N)C#N)C(=O)OC VHMRQLVENVHHJN-UHFFFAOYSA-N 0.000 description 1
PQUSVJVVRXWKDG-UHFFFAOYSA-N methyl 2-bromo-2-methylpropanoate Chemical compound COC(=O)C(C)(C)Br PQUSVJVVRXWKDG-UHFFFAOYSA-N 0.000 description 1
KXZDXMJBQNTYIG-UHFFFAOYSA-N methyl 3,3-dicyano-2,2-dimethylpropanoate Chemical compound COC(=O)C(C)(C)C(C#N)C#N KXZDXMJBQNTYIG-UHFFFAOYSA-N 0.000 description 1
MNOCCIFVTOUKEG-UHFFFAOYSA-N methyl 4-bromothiophene-3-carboxylate Chemical compound COC(=O)C1=CSC=C1Br MNOCCIFVTOUKEG-UHFFFAOYSA-N 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
229960002237 metoprolol Drugs 0.000 description 1
IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
229960001300 metoprolol tartrate Drugs 0.000 description 1
229960003632 minoxidil Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
229950001135 muraglitazar Drugs 0.000 description 1
LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
230000006715 negative regulation of smooth muscle cell proliferation Effects 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
229960001783 nicardipine Drugs 0.000 description 1
LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 description 1
229960002497 nicorandil Drugs 0.000 description 1
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
229960001597 nifedipine Drugs 0.000 description 1
229960000715 nimodipine Drugs 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
229960002460 nitroprusside Drugs 0.000 description 1
238000010606 normalization Methods 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000012053 oil suspension Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 1
229960005117 olmesartan Drugs 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
125000001715 oxadiazolyl group Chemical group 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
150000002923 oximes Chemical class 0.000 description 1
NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical class OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
125000001151 peptidyl group Chemical group 0.000 description 1
229960002582 perindopril Drugs 0.000 description 1
IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
BWSDNRQVTFZQQD-AYVHNPTNSA-N phosphoramidon Chemical compound O([P@@](O)(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC=1[C]2C=CC=CC2=NC=1)C(O)=O)[C@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]1O BWSDNRQVTFZQQD-AYVHNPTNSA-N 0.000 description 1
108010072906 phosphoramidon Proteins 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229960002310 pinacidil Drugs 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
239000003375 plant hormone Substances 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229910003446 platinum oxide Inorganic materials 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
229960002965 pravastatin Drugs 0.000 description 1
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
229960001289 prazosin Drugs 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
UZQBKCWYZBHBOW-UHFFFAOYSA-N propan-2-yl 4-cyclohexyl-2-hydroxy-3-[[3-methylsulfanyl-2-[[2-(morpholine-4-carbonylamino)-3-phenylpropanoyl]amino]propanoyl]amino]butanoate Chemical compound C1CCCCC1CC(C(O)C(=O)OC(C)C)NC(=O)C(CSC)NC(=O)C(NC(=O)N1CCOCC1)CC1=CC=CC=C1 UZQBKCWYZBHBOW-UHFFFAOYSA-N 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
229950003776 protoporphyrin Drugs 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
QLULGIRFKAWHOJ-UHFFFAOYSA-N pyridin-4-ylboronic acid Chemical compound OB(O)C1=CC=NC=C1 QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical group C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
229960001455 quinapril Drugs 0.000 description 1
JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
230000002040 relaxant effect Effects 0.000 description 1
230000004648 relaxation of smooth muscle Effects 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
229960004586 rosiglitazone Drugs 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
238000007127 saponification reaction Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
229960002855 simvastatin Drugs 0.000 description 1
238000005245 sintering Methods 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
229940127296 soluble guanylate cyclase stimulator Drugs 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229960005187 telmisartan Drugs 0.000 description 1
WUBVEMGCQRSBBT-UHFFFAOYSA-N tert-butyl 4-(trifluoromethylsulfonyloxy)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(=O)(=O)C(F)(F)F)=CC1 WUBVEMGCQRSBBT-UHFFFAOYSA-N 0.000 description 1
125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
125000001113 thiadiazolyl group Chemical group 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
LJJKNPQAGWVLDQ-SNVBAGLBSA-N thiorphan Chemical compound OC(=O)CNC(=O)[C@@H](CS)CC1=CC=CC=C1 LJJKNPQAGWVLDQ-SNVBAGLBSA-N 0.000 description 1
239000010936 titanium Substances 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
ZWYDDDAMNQQZHD-UHFFFAOYSA-L titanium(ii) chloride Chemical compound [Cl-].[Cl-].[Ti+2] ZWYDDDAMNQQZHD-UHFFFAOYSA-L 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
125000004306 triazinyl group Chemical group 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 1
150000003672 ureas Chemical class 0.000 description 1
229960004699 valsartan Drugs 0.000 description 1
SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
230000001196 vasorelaxation Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
210000001048 venom Anatomy 0.000 description 1
239000002435 venom Substances 0.000 description 1
231100000611 venom Toxicity 0.000 description 1
229960001722 verapamil Drugs 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000001993 wax Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
210000002268 wool Anatomy 0.000 description 1
150000003752 zinc compounds Chemical class 0.000 description 1

JP2011537535A 2008-11-25 2009-11-16 可溶性グアニレートシクラーゼ活性化剤 Expired - Fee Related JP5501369B2 (ja)